Abbott India Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges. The filing, made pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, includes an Independent Assurance Statement by DNV Business Assurance India Private Limited. The report outlines the company's environmental, social, and governance (ESG) performance, highlighting significant progress in carbon reduction and healthcare access initiatives.

Environmental Performance

The company reported a 73% reduction in absolute Scope 2 carbon emissions at its Mumbai corporate office compared to the 2018 baseline for FY 2025-26. This reduction was achieved through initiatives such as the installation of Modular UPS, light motion sensors, and the use of green power for HVAC operations. At the Goa manufacturing plant, solar photovoltaic panels generated approximately 378 MWh of energy, reducing carbon emissions by 279.58 MT. The plant also implemented water conservation measures, saving 14,600 kiloliters (KL) of water annually by reusing Reverse Osmosis reject water.

Waste and Water Management

Abbott India maintained its internal Zero Waste-to-Landfill (ZWL) certification for both its Goa plant and BKC office. The company reported a total waste generation of 662.86 metric tonnes (MT), with 94.65% recovered through recycling, reusing, or other recovery operations. Total water consumption for the year stood at 65,602.43 KL, with a water intensity of 9.47 KL per INR Crore of turnover.

Social Impact and Healthcare Access

The company advanced its healthcare access programs by upgrading 209 Primary Health Centres (PHCs) into Ayushman Arogya Mandirs across 12 states by the end of FY 2025-26. During the year, 39 PHCs were upgraded, and capacity building was facilitated for over 1,200 Accredited Social Health Activists (ASHAs) and 510 health workers. Additionally, Abbott India screened approximately 4,50,000 people for liver health and 9,50,000 for thyroid conditions across various states and union territories.

Governance and Compliance

The report disclosed that the Office of the Principal Commissioner of CGST & Central Excise, Mumbai East, levied a penalty of ₹2.40 Crores regarding the disallowance of Input Tax Credit for financial years 2018-19, 2019-20, 2021-22, and 2023-24. The company has filed a writ petition before the Bombay High Court in this regard. Furthermore, the Reserve Bank of India (RBI) imposed a compounding amount of ₹0.02 Crores regarding foreign investment limits, which has been settled.

Financial and Operational Metrics

The company reported a turnover of ₹6,846.10 Crores and a net worth of ₹4,774.19 Crores. The median remuneration for Key Managerial Personnel was ₹7.09 Crores for males and ₹1.58 Crores for females. The workforce comprised 3,467 permanent employees and 282 workers, with female representation at 11.16% among employees and 18.44% among workers.

Key ESG Indicators for FY 2025-26

Abbott received approval from the US Food and Drug Administration (FDA) for its HIV Combo Next Assay on June 29, 2026. The regulatory clearance, granted under the 510(k) pathway, allows the company to market the diagnostic assay in the United States. The specific submission reference number for the approval is BK261345.

Regulatory Details

The FDA determined that the HIV Combo Next Assay is substantially equivalent to a predicate device, facilitating its clearance through the 510(k) process. This pathway is generally used for devices that demonstrate safety and effectiveness by comparing them to already legally marketed devices.

Product Information